Isofol Medical AB (publ)

OM:ISOFOL Stock Report

Market Cap: kr113.9m

Isofol Medical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Isofol Medical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth37.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued

May 18
An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued

Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation

Nov 09
Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation

Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans?

May 12
Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans?

Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL)

Apr 08
Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL)

Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment

Mar 03
Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment

We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully

Jan 10
We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Isofol Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OM:ISOFOL - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20231-37-53-53N/A
9/30/20233-53-88-88N/A
6/30/20235-80-120-120N/A
3/31/20239-120-155-155N/A
12/31/202213-160-191-191N/A
9/30/202216-196-190-190N/A
6/30/202218-214-209-209N/A
3/31/202221-209-201-201N/A
12/31/202122-200-188-188N/A
9/30/202136-194-182-182N/A
6/30/202150-173-148-148N/A
3/31/202142-176-142-142N/A
12/31/202037-189-160-160N/A
9/30/202018-192-186-186N/A
6/30/2020N/A-204-183-183N/A
3/31/2020N/A-191-176-176N/A
12/31/2019N/A-162-148-147N/A
9/30/2019N/A-133-106-105N/A
6/30/2019N/A-108-101-101N/A
3/31/2019N/A-90-96-96N/A
12/31/2018N/A-83-92-92N/A
9/30/20180-80-90-90N/A
6/30/20180-82-86-86N/A
3/31/20180-79-73-73N/A
12/31/20170-72-62-62N/A
9/30/20170-77N/A-57N/A
6/30/20170-66N/A-47N/A
3/31/20170-63N/A-46N/A
12/31/20161-65N/A-47N/A
12/31/20150-41N/A-37N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ISOFOL's forecast earnings growth is above the savings rate (0.9%).

Earnings vs Market: Insufficient data to determine if ISOFOL's earnings are forecast to grow faster than the Swedish market

High Growth Earnings: Insufficient data to determine if ISOFOL's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ISOFOL's revenue is forecast to grow faster than the Swedish market.

High Growth Revenue: Insufficient data to determine if ISOFOL's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ISOFOL's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.